Pharmaceutical Product Development (PPD) has secured the fifth renewal of its long-standing contract with the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. The original NIAID/DAIDS contract was awarded in 1990, and with the latest renewal, the relationship will extend until 2024.

The renewed contract covers support for a broad scope of research related to HIV or HIV co-infections that includes monitoring therapeutic trials, prevention trials and vaccines work. As part of the relationship, PPD predicts risks to clinical trial participant safety and data integrity based on measures of site performance and other known risk factors.

“The extension of this contract will allow PPD to provide important comprehensive clinical site and study monitoring services to the NIH in some of the most pivotal and exciting directions in AIDS research,” said William Sharbaugh, chief operating officer of PPD. “We are privileged to continue our collaborative relationship with the NIH, leveraging our considerable resources as one of the world's largest CROs, while capitalizing on our in-depth knowledge of infectious diseases.”

PPD’s most recent contracts, ranging between five and seven years, have involved monitoring for an average of 150 clinical studies per contract.